[多发性骨髓瘤中的细胞外囊介导药物耐药性]
Tomofumi Yamamoto1,2, Yusuke Yamamoto1
1Laboratory of Integrative Oncology, National Cancer Center Research Institute.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 29, 2023
概括
创新的治疗方法改善了多发性骨髓瘤 (MM) 的结果,但药物耐药性仍然存在. 小型细胞外囊泡 (EVs),特别是外体,越来越多地被认为是它们在调解MM药物耐药性的作用.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 多发性骨髓瘤 (MM) 的预后由于新型疗法如蛋白酶体抑制剂和抗体药物而有所改善.
- 治疗耐药性和外骨髓性疾病仍然是MM患者护理的重大挑战.
- 骨髓微环境在MM药物耐药性中起着至关重要的作用,其机制超出了可溶性因素.
研究的目的:
- 总结关于多发性骨髓瘤 (MM) 耐药性的当前知识.
- 审查小细胞外囊泡 (EVs) 的作用,特别是外体,在MM药物耐药性的获得.
主要方法:
- 文献综述,重点关注有关MM药物耐药性的最近文章.
- 对调查小细胞外囊泡 (外体) 对MM治疗耐药性的贡献的研究进行分析.
主要成果:
- 细胞外囊泡 (EVs) 涉及到各种癌症的进展,包括多发性骨髓瘤.
- 小EV,特别是外体,正在成为MM药物耐药性发展的关键调解者.
- 麻疹菌药物耐药性的机制涉及骨髓微环境中的复杂细胞对细胞相互作用.
结论:
- 小的细胞外囊泡 (外体) 是调解多发性骨髓瘤 (MM) 耐药性的关键参与者.
- 了解外体在MM中的作用可能会揭示克服治疗耐药性的新疗法标.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Intralumenal Vesicles and Multivesicular Bodies
3.5K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.5K


